Abstract
The pharmacokinetics of isoniazid and its metabolites acetylisoniazid, isonicotinic acid, and isonicotinuric acid were investigated in man by administering each compound intravenously to a rapid and slow isoniazid acetylator. Isoniazid was measured in blood, and the metabolites were determined in urine. Appropriate models are formulated, with the overall model describing isoniazid and metabolite disposition consisting of 12 compartments.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
H. Meyer and J. Mally. Hydrazine derivatives of carboxylic acids.Monatsh. Chem. 33:393–414 (1912); throughChem. Abst. 6:2073–2074 (1912).
J. M. Robson and F. M. Sullivan. Antituberculosis drugs.Pharmacol. Rev. 15:169–223 (1963).
P. Dineen. Antibacterial drugs. In W. Modell (ed.),Drugs of Choice: 1972–1973, Mosby, St. Louis, 1972, pp. 127–144.
J. H. Peters, K. S. Miller, and P. Brown. Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man.J. Pharmacol. Exp. Ther. 150:298–304 (1965).
G. A. Ellard and P. T. Gammon. Pharmacokinetics of isoniazid metabolism in man.J. Pharmacokin. Biopharm. 4:83–113 (1976).
G. A. Ellard and P. T. Gammon. The pharmacokinetics of isoniazid metabolism in man. In M. Hejzlar, M. Semonský, and S. Masák (eds.),Advances in Antimicrobial and Antineoplastic Chemotherapy, Urban and Schwarzenberg, Munich, 1972, pp. 45–46.
Z. Z. Ziporin, J. S. Chambers, R. R. Taylor, and J. A. Wier. The effect of isoniazid administration on the blood ammonia in tuberculosis patients.Am. Rev. Resp. Dis. 86:21–28 (1962).
Z. Z. Ziporin, J. S. Chambers, N. J. Deter, B. F. Chandler, J. A. Hawkins, and W. C. Morse. Relationship of high isoniazid dosage to blood ammonia and the effect ofl-glutamic acid andl-arginine HCl.Trans. Res. Conf. Pulmonary Dis., 22nd Veterens Administration, Washington, D.C., 1963, pp. 61–63.
G. Porcellati and P. Preziosi. Biological transformation of isonicotinoyl hydrazide.Enzymologia 17:47–54 (1954).
F. Salvatore, G. Porcellati, and D. Patrono. The enzymic degradation of isonicotinoyl hydrazide.Congr. Int. Biochim. Res. Commun., 3rd, Brussels, 1955, p. 34; throughChem. Abst. 50:12147d (1956).
L. H. Schmidt. The problem of the rapid inactivation of isoniazid.Proc. Int. Tuberc. Conf.,16th, Excerpta Medica Foundation, International Congress Series, No. 44, Vol. II, New York, 1961, pp. 487–502.
M. Wenzel. Coupling of isoniazid with amino acids.Naturwissenschaften 42:424 (1955).
M. Wenzel. Studies on the formation of isonicotinuric acid after application of isonicotinic acid hydrazide.Arzneimittel-Forsch. 6:58–59 (1956); throughChem. Abst. 50:8913b (1956).
M. Wenzel. Condensation of isoniazid with glycine and glutamic acid.Arzneimittel-Forsch. 7:662–663 (1957); throughChem. Abst. 52:4932 (1958).
D. A. P. Evans. Genetic variations in the acetylation of isoniazid and other drugs.Ann. N.Y. Acad. Sci. 151:723–733 (1968).
B. N. La Du. Isoniazid and pseudocholinosterase polymorphisms.Fed. Proc. 31:1276–1285 (1972).
H. G. Boxenbaum and S. Riegelman. Determination of isoniazid and some metabolites in biological fluids.J. Pharm. Sci. 63:1191–1197 (1974).
H. G. Boxenbaum, G. S. Jodhka, A. C. Ferguson, S. Riegelman, and T. R. MacGregor. The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man.J. Pharmacokin. Biopharm. 2:211–237 (1974).
E. M. Scott and R. C. J. Wright. Fluorometric determination of isonicotinic acid hydrazide in serum.J. Lab. Clin. Invest. 70:355–360 (1967).
H. B. Kostenbauder, J. B. Portnoff, and J. B. Swintosky. Control of urine pH and its effect on sulfaethidole excretion humans.J. Pharm. Sci. 51:1084–1089 (1962).
L. Z. Benet. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.J. Pharm. Sci. 61:536–541 (1972).
C. M. Metzler.A User's Manual for NONLIN, Technical Report 7292/69/7292/005, Upjohn Co., November 25, 1969, Kalamazoo, Mich.
H. O. Hartley. The modified Gauss-Newton method for the fitting of nonlinear regression functions by least squares.Technometrics 3:269–280 (1961).
S. Riegelman, J. C. K. Loo, and M. Rowland. Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.J. Pharm. Sci. 57:117–123 (1968).
J. C. K. Loo and S. Riegelman. Assessment of pharmacokinetic constants from post infusion blood curves obtained after I.V. infusion.J. Pharm. Sci. 59:53–55 (1970).
H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokin. Biopharm. 2:123–148 (1974).
H. G. Boxenbaum. Pharmacokinetics of isoniazid in man. Dissertation deposited in the library, San Francisco Medical Center, University of California, San Francisco.
H. Smith.The Kidney: Structure and Function in Health and Disease, Oxford University Press, New York, 1951, p. 545.
F. D. Moore, K. H. Olesen, J. D. McMurrey, H. V. Parker, M. R. Ball, and C. M. Bogden.The Body Cell Mass and its Supporting Environment: Body Composition in Health and Disease, Saunders, Philadelphia, pp. 483–490.
C. M. Metzler, Upjohn Co., Kalamazoo, Mich., personal communication; through L. Z. Benet, School of Pharmacy, University of California, San Francisco.
M. Rowland, L. Z. Benet, and S. Riegelman. Two compartment model for a drug and its metabolite: Application to acetylsalicylic acid pharmacokinetics.J. Pharm. Sci. 59:364–367 (1970).
K. A. McMahon and W. J. O'Reilly. Pharmacokinetics of three sulfonamides in the rabbit.J. Pharm. Sci. 61:518–523 (1972).
E. Nelson and I. O'Reilly. Kinetics of sulfisoxazole acetylation and excretion in humans.J. Pharmacol. Exp. Ther. 129:368–372 (1960).
W. J. Westlake. Problems associated with analysis of pharmacokinetic models.J. Pharm. Sci. 60:882–885 (1971).
J. R. Mitchell, U. P. Thorgeirsson, M. Black, J. A. Timbrell, W. R. Snodgrass, W. Z. Potter, D. J. Jollow, and H. R. Keiser. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites.Clin. Pharmacol. Ther. 18:70–79 (1975).
E. Ackerman, E. H. Strickland, J. B. Hazelrig, and L. C. Gatewood. Computers in biomathematical applications.Clin. Pharmacol. Ther. 8:170–184 (1967).
J. W. Jenne and M. Orser. Partial purification and properties of the isoniazid transacetylase in human liver: Its relationship to the acetylation ofp-aminosalicylic acid.J. Clin. Invest. 44:1992–2002 (1965).
T. Suzuki and Y. Saitoh. Pharmacokinetic analysis of blood level data interpreted by a two-compartment model.Chem. Pharm. Bull. 21:1458–1469 (1973).
D. Lalka, W. J. Jusko, and T. J. Bardos. Reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems. II. Comparative pharmacokinetics in dogs.J. Pharm. Sci. 64:230–235 (1975).
M. Gibaldi, R. Nagashima, and G. Levy. Relationship between drug concentration in plasma or serum and amount of drug in the body.J. Pharm. Sci. 58:193–197 (1969).
J. G. Wagner. Intrasubject variation in elimination half-lives of drugs which are appreciably metabolized.J. Pharmacokin. Biopharm. 1:165–173 (1973).
Author information
Authors and Affiliations
Additional information
This article is dedicated to the memory of Dr. L. Strait, teacher and friend.
This work was supported in part by National Institutes of Health Training Grants GM 00728 and GM 16496, U.S. Public Health Service, Bethesda, Md.
Abstracted in part from a dissertation submitted by Harold G. Boxenbaum to the Graduate Division, University of California, San Francisco Medical Center, San Francisco, California, in partial fulfillment of the requirements for the Doctor of Philosophy degree.
American Foundation for Pharmaceutical Education Fellow.
7 A Consulting Editor served as the Journal Editor for the manuscript during its review process.
Rights and permissions
About this article
Cite this article
Boxenbaum, H.G., Riegelman, S. Pharmacokinetics of isoniazid and some metabolites in man. Journal of Pharmacokinetics and Biopharmaceutics 4, 287–325 (1976). https://doi.org/10.1007/BF01063121
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01063121